Important Safety Information
This site is intended for US healthcare professionals only. U.S. healthcare professionals only. Visit patient site

FreeStyle Libre 14 day system  //  Clinical Evidence

REAL-WORLD
EVIDENCE

Analyzing the impact of
FreeStyle Libre 14 day system

FreeStyle Libre 14 day system is
making a real impact on patient outcomes.

Reduced A1C

Average A1C reduction of 0.56% across a variety of studies and a broad population1

Reduced time in hypoglycemia

Increased monitoring with FreeStyle Libre 14 day system was associated with 31% less time in hypoglycemia2

Increased monitoring frequency

FreeStyle Libre 14 day system users monitored their glucose more often than the ADA guidelines for SMBG*2,3

Increased time in target range

Increased monitoring with FreeStyle Libre 14 day system was associated with 44% more time in range2

META-ANALYSIS

FreeStyle Libre 14 day system significantly reduced A1C
across a variety of studies and a broad population1

The higher the initial A1C, the greater the A1C reduction

No significant differences were seen based on
study length, type of diabetes, or age

REAL-WORLD DATA

Increased monitoring frequency

FreeStyle Libre 14 day system users monitored their glucose more often than the ADA guidelines for SMBG*2,3

FreeStyle Libre 14 day system is the first and only 14 day personal
continuous glucose monitoring (CGM) solution clinically proven to
reduce time spent in hypoglycemia4,5

Reduced time in hypoglycemia, increased time in range

Increased monitoring with FreeStyle Libre 14 day system was associated with:

Scan frequency sustained

Increased testing frequency is sustained over time with FreeStyle Libre 14 day system6

Improvements observed within first 2 days

Hypoglycemia reductions occur within the first 2 days of wearing FreeStyle Libre 14 day sensor7

Reduction in hypoglycemia sustained

Reductions in hypoglycemia are sustained over a 6-month period and reflect findings from randomized controlled trials8

Want a professional CGM system with the same sensor technology?

Want a sales rep to provide more information?

* Self-monitoring of blood glucose

Reference: 1. Seibold A, Ells S, Schlaeger C, Welsh Z. A meta-analysis of real-world observational studies on the impact of flash glucose monitoring on glycemic control as measured by HbA1c. Poster presented at: 78th Scientific Sessions; June 2018; Orlando, FL. 2. Ajjan R. Insights from real world use of flash continuous glucose monitoring. Symposium conducted at: American Diabetes Association 78th Scientific Sessions; June 2018; Orlando, FL. 3. American Diabetes Association. Standards of medical care in diabetes--2018. https://doi.org/10.2337/dc18-Sint01. January 2018. 4. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked randomised controlled trial. Lancet. 2016;388{10057):2254-2263. 5. Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55-73. 6. Jangam S, Dunn T, Xu Y, Hayter G, Ajjan R. Sustained improvement in glycemic control following flash glucose monitoring: a worldwide observational analysis. Poster presented at: the 11th International Conference on Advanced Technologies & Treatments for Diabetes; February 2018; Vienna, Austria. 7. Dunn Timothy., et al. Evidence of a strong association between frequency of flash glucose monitoring and glucose control measures during real-world usage. E-poster presented at: The 10th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2017); February 2017; Paris, France. 8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked randomised controlled trial. Lancet. 2016;388{10057):2254-2263.

ADC-09305 Ver 2.0 10/18

Top

You are about to leave for a 3rd party website

The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?

Thank you for submitting your details. We will contact you as soon as possible.